3
In order to investigate the reaction kinetics, an experiment was
worked well with this method, while the tertiary carboxylic acid
carried out in absence of the acid coupling partner. In this
experiment it was shown that the CMPI reagent reacted with
sulfonamide 6 over 1 hour to form 7 with 77% conversion (Scheme
3). Subsequent addition of acid 5 to the reaction mixture did not
result in the formation of the acyl sulfonamide product, suggestive
(3o) afforded lower but acceptable yield (36%).
The scope of the sulfonamides (2b –f) with benzoic acid 1a was
explored next (Table 2). Simple aliphatic sulfonamides (Entry 1,
2) behaved similarly as methanesulfonamide with good isolated
yields. Gratifyingly, aromatic sulfonamides (Entry 3 - 5) also
coupled well to give good yields of the desired products.
of a competitive reaction between the acid and the sulfonamide
11
with CMPI.
Interestingly, the carboxylic acids are activated
significantly faster by the CMPI reagent than are the sulfonamides,
which presumably allows for good conversion to the acyl
sulfonamide product with little to no pyridin-2(1H)-
ylidene)methanesulfonamide-derived side products.
Table 2. Sulfonamide scope
O
O
O
O
conditions
O
O
S
OH
N
R2
+
S
H2N
2b - f
R2
H
Scheme 3. Reaction of sulfonamide 6 with the Mukaiyama
reagent
1a
4b - f
O
O
N
O
a
O
S
S
+
N+
Cl
Yield
Yield
(%)a
Entry
R2
Entry
4
R2
S
S
N
NH2
I-
Br
(%)a
Br
6
7
a: 1.0 mmol CMPI, 1.7 mmol of 6, 0.04 mmol DMAP, 2.5 mmol of TEA,
DCM (0.3 M), rt.
1
83
84
87
4b
Cl
In conclusion, we have described the development of a quick
and efficient preparative procedure to access acyl sulfonamide
derivatives from carboxylic acids using the CMPI reagent. An
excess of sulfonamide (2.0 eq) can be used to drive the reaction to
completion within 1 hour of stirring at room temperature in most
cases. When the sulfonamide is the limiting reagent, a 1:1 ratio of
carboxylic acid to sulfonamide can be used in conjunction with a
longer reaction time to obtain satisfactory yields. This method is
also amenable to large scale synthesis. We were able to routinely
utilize this facile synthesis of acyl sulfonamides in a drug
discovery program focused on the preparation of Nav1.7 inhibitors
that allowed an expedient expansion the SARs in a series of
analogs.12
4e
2
3
89
83
5
Cl
4c
4d
4f
aIsolated yield, 1 h.
To demonstrate the utility of this method, LY573636, an
antitumor agent that possesses an acyl sulfonamide moiety, was
prepared by this method (Scheme 2). LY573636 was obtained in
65% yield (0.6 mmol scale) using the standard reaction
conditions.9 When conducted on a 6 mmol scale, LY573636 was
obtained 76% yield after 1 hour of stirring. Interestingly, 7 was
isolated as a by-product in 15% yield, believed to have arisen from
the CMPI reagent reacting with the sulfonamide (Scheme 3). In
the small scale screening reactions only a few of the couplings
showed a small amount of the corresponding sulfonamide
adduct.10
Acknowledgments
We gratefully acknowledge Drs. Carolyn Dzierba and Nicholas Meanwell for
careful reading of this manuscript and Robert Langish, Linping Wang for
HRMS analysis .
References and Notes
1.
(a) Bowsher, M.; Hiebert, S.; Li, R.; Wang, A. X.; Friborg, J.; Yu,
F.; Hernandez, D.; Wang, Y-K.; Klei, H; Rajamani, R.; Mosure, K;
Knipe, J. O.; Meanwell, N. A.; McPhee, F.; Scola, P. M. Bioorg.
Med. Chem. Lett. 2018, 28, 43. (b) Sun, L.Q.; Mull, E.; Zheng, B.;
D'Andrea, S.; Zhao, Q.; Wang, A. X.; Sin, N.; Venables, B. L.; Sit,
S-Y.; Chen, Y.; Chen, J.; Cocuzza, A.; Bilder, D. M.; Mathur, A.;
Rampulla, R.; Chen, B.C.; Palani, T.; Ganesan, S.; Arunachalam,
P.N.; Falk, P.; Levine, S.; Chen, C.; Friborg, J.; Yu, F.; Hernandez,
D.; Sheaffer, A.K.; Knipe, J.O.; Han, Y. H.; Schartman, R.; Donoso,
M.; Mosure, K.; Sinz, M. W.; Zvyaga, T.; Rajamani, R.; Kish, K.;
Tredup, J.; Klei, H. E.; Gao, Q.; Ng, A.; Mueller, L.; Grasela, D.
M.; Adams, S.; Loy, J.; Levesque, P. C.; Sun, H.; Shi, H.; Sun, L.;
Warner, W.; Li, D.; Zhu, J.; Wang, Y. K.; Fang, H.; Cockett, M. I.;
Meanwell, N. A.; McPhee, F.; Scola, P. M. J. Med. Chem. 2016, 59,
8042; (c) Ammazzalorso, A.; De Filippis, B.; Giampietro, L.;
Amoroso, R.; Chem. Biol. Drug Des. 2017, 90, 1094; (d) DiMauro,
E. F.; Altmann, S.; Berry, L. M,.; Bregman, H.; Chakka, N.; Chu-
Moyer, M.; Bojic, E. F.; Foti, R. S.; Fremeau, R.; Gao, H.;
Gunaydin, H.; Guzman-Perez, A.; Hall, B. E.; Huang, H.; Jarosh,
M.; Kornecook, T.; Lee, J.; Ligutti, J.; Liu, D.; Moyer, B. D.;
Ortuno, D.; Rose, P. E.; Schenkel, L. B.; Taborn, K.; Wang, J.;
Wang, Y.; Yu, V.; Weiss, M. M. J. Med. Chem. 2016, 59, 7818.
Scheme 2. Synthesis of LY573636
Cl
O
O
Cl
O
O
O
a
S
O
N
+
OH
S
H
S
S
NH2
Br
Cl
Cl
Br
5
6
LY573636
O
O
N
S
S
N
Br
7
a: 1.2 eq CMPI, 0.05 eq DMAP, 3.0 eq of TEA, CH2Cl2 (0.3 M), rt.